Langerhans Cell-Rich Fibroinflammatory Pulmonary Lesion Presenting as a Pulmonary Mass: A Case Report

Technical Summary: Langerhans Cell-Rich Fibroinflammatory Pulmonary Lesion Presenting as a Pulmonary Mass

Problem Statement
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare clonal myeloid neoplasm driven by MAPK pathway mutations, typically affecting young adult smokers and characterized by nodulocystic upper-lobe disease with bronchiolocentric infiltration. However, Langerhans cells (LC) expressing CD1a and langerin (CD207) can also accumulate in reactive, non-clonal inflammatory settings. A significant diagnostic challenge arises when these reactive LC-rich infiltrates mimic clonal histiocytosis radiographically and histologically. Misclassification can lead to inappropriate management, ranging from unnecessary systemic targeted therapies (e.g., BRAF/MEK inhibitors) for reactive processes to under-treatment of true neoplasms. The specific diagnostic difficulty is compounded when lesions present as localized masses with atypical extrapulmonary involvement, such as cervical lymphadenopathy, which is not a standard feature of reactive LC proliferations.

Methodology
This study presents a single case report of a 71-year-old woman with minimal remote tobacco use (<10 pack-years, ceased 40 years prior) presenting with progressive dyspnea, weight loss, and a unilateral FDG-avid pulmonary mass with extensive mediastinal and cervical lymphadenopathy encasing neck vasculature. The diagnostic approach involved a multidisciplinary workflow:

1. Imaging: CT and PET scans revealed progressive consolidation and hypermetabolic lymphadenopathy.
2. Biopsy Sequence: Initial CT-guided core needle biopsy and navigational bronchoscopy with endobronchial ultrasound (EBUS) were nondiagnostic for malignancy or infection. A subsequent core needle biopsy of a supraclavicular node was also negative.
3. Surgical Intervention: Video-assisted thoracoscopic surgery (VATS) wedge resection of the lung nodule and mediastinal lymph node resection was performed for definitive tissue diagnosis.
4. Pathological and Molecular Analysis: Resected tissue underwent comprehensive histopathologic evaluation, including immunohistochemistry (IHC) for CD1a, CD207 (langerin), S-100, Cyclin D1, IgG4, ALK-1, and lymphocyte markers (CD20, CD3). Bacterial, fungal, and mycobacterial cultures were performed. Next-generation sequencing (NGS) was utilized to screen for MAPK pathway mutations (e.g., BRAF V600E, MAP2K1).
5. Therapeutic Trial: Based on the consensus diagnosis, the patient was treated with prednisone (1 mg/kg daily) for six weeks followed by a taper.
6. Follow-up: Clinical and radiographic (CT) assessments were conducted at 6 weeks and 3 months post-therapy completion.

Key Results

• Histopathology: The wedge resection revealed prominent benign fibroinflammatory infiltrates with increased CD1a⁺/CD207⁺ cells. Crucially, the lesion lacked the canonical features of PLCH: there was no bronchiolocentric architecture, no airway destruction, no granuloma formation, and no cystic remodeling. The LCs surrounded compressed alveoli and were negative for Cyclin D1 overexpression.
• Exclusion of Differentials: The pathology ruled out IgG4-related disease (negative for storiform fibrosis, obliterative phlebitis, and elevated IgG4/IgG ratio), Erdheim-Chester disease (inconsistent immunophenotype), and malignancy. Comprehensive hematologic evaluation was negative.
• Molecular Findings: NGS confirmed the absence of MAPK pathway mutations, supporting a non-clonal etiology.
• Clinical Response: The patient demonstrated rapid clinical and radiographic improvement following corticosteroid therapy. A repeat CT at 6 weeks showed resolution of the neck mass and marked improvement in lung abnormalities. At 3 months post-taper, the patient remained in sustained remission with no recurrence, and residual opacities were attributed to post-inflammatory scarring.

Significance and Claims
The paper asserts that LC-rich pulmonary infiltrates are not synonymous with PLCH. The authors highlight that immunophenotypic positivity for CD1a⁺/CD207⁺ alone is insufficient for diagnosing Langerhans cell histiocytosis. This case is significant for several reasons:

1. Diagnostic Complexity: It illustrates a reactive LC-rich fibroinflammatory process that closely mimicked clonal histiocytosis, including an unusual pattern of extrapulmonary cervical nodal involvement encasing major vasculature—a presentation not previously reported in the context of reactive LC infiltrates.
2. Multidisciplinary Necessity: The authors emphasize that accurate distinction between reactive and clonal LC proliferations requires the integration of clinical context (e.g., smoking history, age), radiographic patterns (absence of cysts/nodulocystic disease), histopathologic architecture (absence of bronchiolocentric destruction), and molecular data (absence of MAPK mutations).
3. Therapeutic Implications: In the era of MAPK-targeted therapies, misclassification poses a risk of exposing patients to unnecessary systemic immunosuppression or targeted inhibitors. The rapid response to corticosteroids and sustained remission off-therapy in this case supports the diagnosis of a reactive process and underscores the importance of avoiding overtreatment.
4. Etiological Speculation: While the authors note the patient's history of significant dust exposure during home renovation as a potential inflammatory trigger, they maintain that the causal relationship remains speculative. Similarly, the patient's history of psoriasis is noted as a potential contributor to immune dysregulation but is not claimed as a definitive cause.

The paper concludes that accurate diagnosis relies on a comprehensive clinicopathologic correlation to prevent misclassification, ensuring that patients receive appropriate management rather than unnecessary targeted therapy.